IL1B and COVID-19: Interestingly, mounting evidence from clinical studies suggests that this PPAR agonist prevents the ARDS/ALI in COVID-19 patients by downregulating NF-κB and JAK/STAT signaling and then reducing TNF-α, IL1β, and IL6 levels.